Murase Kazuyuki, Matsunaga Takuya, Sato Tsutomu, Kuribayashi Kageaki, Kogawa Katsuhisa, Kawano Yutaka, Okamoto Tetsuro, Takayama Tetsuji, Watanabe Hideki, Niitsu Yoshiro, Hirayama Yasuo
Fourth Department of Internal Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8543, Japan.
Int J Clin Oncol. 2003 Dec;8(6):391-4. doi: 10.1007/s10147-003-0349-1.
Although T-prolymphocytic leukemia (T-PLL) is characterized by organ infiltration, small-intestinal involvement is rare. We performed an unrelated allogeneic bone marrow transplantation in a patient with T-PLL who had multiple lymphomatous polyposis of the small intestine refractory to combination chemotherapy (cyclophosphamide, vincristine, and prednisolone [COP] and fludarabine plus cyclophosphamide). The patient developed no graft-versus-host disease (GVHD) and remains in complete remission 16 months after the transplantation. T-PLL is usually refractory to chemotherapy and is a T-cell malignancy with poor prognosis. There have been several reports on allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for T-PLL, but none on allo-HSCT for T-PLL patients with intestinal involvement. It is suggested that allo-HSCT may improve the prognosis in patients with T-PLL involving the small intestine.
尽管T细胞幼淋巴细胞白血病(T-PLL)以器官浸润为特征,但小肠受累情况罕见。我们对一名患有T-PLL且小肠多发淋巴瘤性息肉病的患者进行了非亲缘异基因骨髓移植,该患者对联合化疗(环磷酰胺、长春新碱和泼尼松龙[COP]以及氟达拉滨加环磷酰胺)耐药。该患者未发生移植物抗宿主病(GVHD),移植后16个月仍处于完全缓解状态。T-PLL通常对化疗耐药,是一种预后较差的T细胞恶性肿瘤。关于T-PLL的异基因造血干细胞移植(allo-HSCT)已有多篇报道,但尚无针对小肠受累的T-PLL患者进行allo-HSCT的报道。提示allo-HSCT可能改善小肠受累的T-PLL患者的预后。